

## PRODUCT INFORMATION

<b>Clone ID</b>	DMC463
<b>Target</b>	CD142
<b>Synonyms</b>	TF; Coagulation factor III; F3
<b>Host Species</b>	Rabbit
<b>Description</b>	PE-conjugated Anti-CD142 antibody(DMC463); IgG1 Chimeric mAb
<b>Delivery</b>	Under Development
<b>Uniprot ID</b>	P13726
<b>IgG type</b>	Rabbit/Human Fc chimeric IgG1
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	Human
<b>Applications</b>	Flow Cyt
<b>Recommended Dilutions</b>	Flow Cyt 1:100
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Liquid□PBS with 0.05% Proclin300, 1% BSA
<b>Storage &amp; Shipping</b>	Store at 2°C-8°C for 6 months
<b>Background</b>	<p>This gene encodes coagulation factor III which is a cell surface glycoprotein. This factor enables cells to initiate the blood coagulation cascades; and it functions as the high-affinity receptor for the coagulation factor VII. The resulting complex provides a catalytic event that is responsible for initiation of the coagulation protease cascades by specific limited proteolysis. Unlike the other cofactors of these protease cascades; which circulate as nonfunctional precursors; this factor is a potent initiator that is fully functional when expressed on cell surfaces; for example; on monocytes. There are 3 distinct domains of this factor: extracellular; transmembrane; and cytoplasmic. Platelets and monocytes have been shown to express this coagulation factor under procoagulatory and proinflammatory stimuli; and a major role in HIV-associated coagulopathy has been described. Platelet-dependent monocyte expression of coagulation factor III has been described to be associated with Coronavirus Disease 2019 (COVID-19) severity and mortality. This protein is the only one in the coagulation pathway for which a congenital deficiency has not been described. Alternate splicing results in multiple transcript variants.[provided by RefSeq; Aug 2020]</p>
<b>Usage</b>	Research use only
<b>Conjugate</b>	PE-conjugated
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.



PE-conjugated Anti-CD142 antibody(DMC463); IgG1 Chimeric mAb

Cat. No. DMC100463P



DIMABIO CONFIDENTIAL

Address: Wuhan institute of  
Biotechnology B7, Biolake No.666  
Gaoxin Road, Wuhan, Hubei, China  
Telephone: +1 2409940618(USA)  
/+86-18062749453(China)  
/+86-400-006-0995(China)

Email: [info@dimabio.com](mailto:info@dimabio.com)  
Website: [www.dimabio.com](http://www.dimabio.com)

